These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3221745)

  • 41. Concentration-effect relations of 5-hydroxypropafenone in normal subjects.
    Haefeli WE; Vozeh S; Ha HR; Taeschner W; Follath F
    Am J Cardiol; 1991 May; 67(11):1022-6. PubMed ID: 2018005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.
    Cai WM; Chen B; Cai MH; Zhang YD
    Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):720-4. PubMed ID: 10678105
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacology and beta-blocking efficacy of propafenone.
    Barbey JT
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S41-3. PubMed ID: 1723117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enantiomers: implications and complications in developmental pharmacology.
    Eichelbaum M
    Dev Pharmacol Ther; 1992; 18(3-4):131-4. PubMed ID: 1306801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.
    Pritchett EL; Smith WM; Kirsten EB
    J Clin Pharmacol; 1988 Jul; 28(7):619-24. PubMed ID: 3063727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.
    Chen B; Cai WM
    Acta Pharmacol Sin; 2003 Dec; 24(12):1277-80. PubMed ID: 14653957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers.
    Chen X; Zhong D; Blume H
    Eur J Pharm Sci; 2000 Mar; 10(1):11-6. PubMed ID: 10699379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A; Boriani G; Marchesini B; Strocchi E; Tomasi L; Balducelli M; Frabetti L; Ambrosioni E; Magnani B
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):281-7. PubMed ID: 2285622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.
    Giani P; Landolina M; Giudici V; Bianchini C; Ferrario G; Marchi S; Riva E; Latini R
    Eur J Clin Pharmacol; 1988; 34(2):187-94. PubMed ID: 3383990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
    Ujhelyi MR; O'Rangers EA; Fan C; Kluger J; Pharand C; Chow MS
    Clin Pharmacol Ther; 1993 Jan; 53(1):38-48. PubMed ID: 8422740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enantioselective pharmacokinetics of primaquine in healthy human volunteers.
    Tekwani BL; Avula B; Sahu R; Chaurasiya ND; Khan SI; Jain S; Fasinu PS; Herath HM; Stanford D; Nanayakkara NP; McChesney JD; Yates TW; ElSohly MA; Khan IA; Walker LA
    Drug Metab Dispos; 2015 Apr; 43(4):571-7. PubMed ID: 25637634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonlinear kinetics of propafenone metabolites in healthy man.
    Vozeh S; Haefeli W; Ha HR; Vlcek J; Follath F
    Eur J Clin Pharmacol; 1990; 38(5):509-13. PubMed ID: 2379537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone--a novel antiarrhythmic agent.
    Koytchev R; Alken RG; Mayer O; Smith I; Greenwood M
    Eur J Clin Pharmacol; 1996; 50(4):315-9. PubMed ID: 8803526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tissue distribution of propafenone in the rat after intravenous administration.
    Fernández J; Lligoña L; Puigdemont A; Guitart R; Riu JL; Arboix M
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):23-7. PubMed ID: 1936057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans.
    Jarman M; Milsted RA; Smyth JF; Kinas RW; Pankiewicz K; Stec WJ
    Cancer Res; 1979 Jul; 39(7 Pt 1):2762-7. PubMed ID: 445480
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacology of thalidomide.
    Eriksson T; Björkman S; Höglund P
    Eur J Clin Pharmacol; 2001 Aug; 57(5):365-76. PubMed ID: 11599654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes.
    Fasinu PS; Avula B; Tekwani BL; Nanayakkara NP; Wang YH; Bandara Herath HM; McChesney JD; Reichard GA; Marcsisin SR; Elsohly MA; Khan SI; Khan IA; Walker LA
    Malar J; 2016 Apr; 15():224. PubMed ID: 27093859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction between digoxin and propafenone.
    Calvo MV; Martin-Suarez A; Martin Luengo C; Avila C; Cascon M; Domínguez-Gil Hurlé A
    Ther Drug Monit; 1989; 11(1):10-5. PubMed ID: 2911842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.
    Anzenbacherová E; Anzenbacher P; Perlik F; Kvetina J
    Int J Clin Pharmacol Ther; 2000 Sep; 38(9):426-9. PubMed ID: 11020029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers.
    Hinderling PH; Tendolkar A; Dee CM; Barr WH; Seiberling M; Duerr H
    J Clin Pharmacol; 1995 Jul; 35(7):721-9. PubMed ID: 7560253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.